Biostax Corp.

Pharmaceutical Preparations·WINTER PARK, FL

CEO

Griffin Noreen

CFO

Farmer Glen A

Summary Financials

Revenue

$113,500

+0.0% YoY

FY 2020

Adj. EBITDA

-$1.2M

-1024.5% margin

FY 2023

Net Income

-$3.5M

-3115.5% margin

FY 2023

EPS (Diluted)

-$0.10

FY 2023

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$150,491

FY 2023

Total Debt

$696,478

FY 2014

Net Debt

$545,987

FY 2014

Enterprise Value

—

Debt / EBITDA

-0.5x

FY 2020

EV / EBITDA

—

Employees

—

Revenue

$113,500

+0.0% YoY

FY 2020

Adj. EBITDA

-$1.2M

-1024.5% margin

FY 2023

Net Income

-$3.5M

-3115.5% margin

FY 2023

EPS (Diluted)

-$0.10

FY 2023

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$150,491

FY 2023

Total Debt

$696,478

FY 2014

Net Debt

$545,987

FY 2014

Enterprise Value

—

Debt / EBITDA

-0.5x

FY 2020

EV / EBITDA

—

Employees

—